Implications of the fragility of opioid agonist treatment continuity on hepatitis C re-exposure concerns among people in prison
A qualitative study
Bibliographic Data
| ID | 14909006 |
|---|---|
| Authors | Lise Lafferty (0000-0002-8533-2957, UNSW Sydney, corresponding author), Tracey Brown (0000-0002-8112-6873), Tracey J Brown (0000-0003-4381-5974, New South Wales Department of Health), Colette McGrath (New South Wales Department of Health), Thomas A Wright (0000-0002-7955-5679, Services Australia), Thomas Wright (0000-0002-3475-0016), C R Henderson (0000-0001-7264-2676, Burnet Institute), Andrew R Lloyd (0000-0001-6277-8887, New South Wales Institute of Psychiatry), J Grebely (0000-0002-1833-2017, New South Wales Institute of Psychiatry), Carla Treloar (0000-0002-8230-0386, New South Wales Department of Health) |
| Year | 2025 |
| Volume | 142 |
| Pages | 104831 |
| Publication date | 2025-08-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2025.104831 |
| PMID | 40393090 |
| OpenAlex | W4410487249 |
| Language | EN |
| Citations received | 1 |
| References cited | 27 |
Continuity of OAT and HCV care remains a fragile experience for people who cycle in and out of incarceration. People who miss their OAT appointment in the community might wait several months upon re-incarceration to re-enter the OAT program. This leaves people vulnerable to injection sharing in custody and, subsequently, increased risk of HCV (re-)exposure while waiting to recommence OAT or to return to the optimal dosing level
Criminology · Fragility · Hepatitis C · Opioid · Prison · Psychiatry · Qualitative research · Sociology · Chemistry · Hepatitis B Virus Studies · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · Medicine · Psychology · Social Psychology · Internal Medicine · Virology
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs
Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs
Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B
Experiencing uncertain HIV treatment delivery in a transitional setting
The social life of HIV care
Structural competency in the post-prison period for people who inject drugs
Injecting risk behaviours amongst people who inject drugs
Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up
Interventions to prevent HIV and Hepatitis C among people who inject drugs
A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in prisons
Health and correctional staff acceptability of depot buprenorphine in NSW prisons
Trust and service engagement among people who inject drugs after release from prison
Conceptualising access in the direct-acting antiviral era
Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons
Are We There Yet? Data Saturation in Qualitative Research
Understanding fragility
The time of cure
| Unique citing works | 1 |
|---|---|
| Citations per year | 1 |
| Citation span | 2026 - 2026 (1) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 1 |